Market Movers (8-K)
See all →NYSE
Genpact Limited announced robust first-quarter 2026 financial results, driven by a significant acceleration in Advanced Technology Solutions revenue.
NYSE
Genpact Limited held its 2026 annual general meeting, where shareholders voted on director elections, executive compensation, and the appointment of KPMG as the independent auditor.
NYSE
Genpact Limited announced robust financial results for full year 2025, driven by strong growth in Advanced Technology Solutions and a 10% increase in its quarterly dividend.
Better than expected
NYSE
Genpact's subsidiaries successfully completed a $350 million public offering of 4.950% Senior Notes due 2030, guaranteed by the parent company and Genpact Luxembourg.
Capital raise
NYSE
Genpact Limited reported strong third quarter 2025 financial results, with net revenues up 6.6% to $1.291 billion and adjusted diluted EPS increasing 14.1% to $0.97, exceeding guidance.
Better than expected
NYSE
Genpact Limited announced the appointment of Anthony Radesca as its new Senior Vice President and Chief Accounting Officer, effective September 29, 2025.
Quarterly Earnings (10-Q)
See all →NYSE
Genpact Limited announced its second quarter 2026 financial results, showcasing a 7.1% increase in net revenues driven by robust demand for its Advanced Technology Solutions.
NYSE
Genpact reported Q1 2026 net revenue of $1.296 billion, a 6.7% increase year-over-year, driven by growth in advanced technology and AI solutions.
Capital raise
NYSE
Genpact Limited reported a 6.6% increase in net revenues for the third quarter of 2025, driven by robust demand for Data-Tech-AI and Advanced Technology Solutions, alongside strategic acquisitions and increased dividends.
Capital raise
Better than expected
NYSE
Genpact Limited announced robust financial results for the second quarter and first half of 2025, driven by increased demand for advanced technology solutions and strategic acquisitions.
Better than expected
NYSE
Genpact's Q1 2025 shows revenue growth and improved profitability driven by Data-Tech-AI services and operational efficiencies.
Better than expected
NYSE
Genpact's Q3 2024 results show a 6.6% increase in revenue year-over-year, driven by growth in both Data-Tech-AI and Digital Operations services.
Better than expected
Annual Reports (10-K)
NYSE
Genpact Limited reported a 6.6% increase in net revenues to $5.1 billion in 2025, driven by strong demand for Advanced Technology Solutions and strategic acquisitions, while navigating global economic uncertainties and tax challenges.
Better than expected
Capital raise
NYSE
Genpact's 2024 annual report reveals a 6.5% increase in net revenues, reaching $4.8 billion, fueled by growth in both Digital Operations and Data-Tech-AI services.
Worse than expected
NYSE
Genpact Limited's 2023 annual report highlights a 2.4% revenue increase to $4.5 billion, alongside strategic investments in AI and employee development.
Worse than expected
Insider Trading (Form 4)
See all →NYSE
Form 4: Genpact President Sells Shares
Sameer Dewan, Senior Vice President of Genpact LTD, sold 14,972 shares of common stock on August 14, 2026 for $34.10 per share.
NYSE
Form 4: Genpact President Sells Shares
Anil Nanduru, Senior Vice President of Genpact LTD, sold 29,095 shares of common stock on August 11, 2026.
NYSE
Genpact Limited director John M. Hinshaw was granted 6,521 restricted share units as part of the company's incentive compensation plan.
NYSE
Director CeCelia Morken was granted 6,521 restricted share units (RSUs) as part of the Genpact Limited 2017 Omnibus Incentive Compensation Plan.
NYSE
Genpact Limited director Carol Lindstrom was granted 6,521 restricted share units as part of the company's incentive compensation plan.
NYSE
Director Nicholas C. Gangestad was granted 6,521 restricted share units as part of Genpact's 2017 Omnibus Incentive Compensation Plan.
Proxy Statements (Def-14A)
See all →NYSE
Genpact issues a supplement to its proxy statement to address concerns raised by Glass Lewis regarding the disclosure of racial/ethnic minority demographic information about its director nominees.
NYSE
Genpact Limited has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.
NYSE
Genpact exceeded expectations in 2024 with strong financial results and is prioritizing innovation with new AI offerings in 2025.
Better than expected
NYSE
Genpact clarifies the circumstances surrounding a former executive's departure and equity award vesting in response to an ISS recommendation against the Say-on-Pay proposal.
NYSE
Genpact Limited has filed a definitive proxy statement with the Securities and Exchange Commission.
NYSE
Genpact's 2024 proxy statement highlights a solid financial performance in 2023, driven by digital operations and Data-Tech-AI services, with a strategic focus on strengthening its foundation for future growth through AI integration and leadership development.
Schedule 13G - Passive Investments
See all →NYSE
AQR Capital Management reports a beneficial ownership stake of 5.07% in Genpact LTD as of June 30, 2026.
NYSE
Vanguard Portfolio Management has reported a beneficial ownership of 6.14% in Genpact Ltd, holding over 10.4 million shares.
NYSE
FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 10,405,025.34 shares, representing 6.1% of Genpact Ltd's common stock, as of June 30, 2026.
NYSE
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported beneficial ownership of 11,278,646 shares of Genpact LTD common stock, representing 6.64% of the class.
NYSE
Vanguard Capital Management has filed a Schedule 13G reporting a 5.1% beneficial ownership stake in Genpact Ltd.
NYSE
Vanguard Portfolio Management has disclosed beneficial ownership of 5.12% of Genpact Ltd's common stock as of March 31, 2026.